Detalhe da pesquisa
1.
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma.
Ann Hematol
; 102(2): 385-392, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36645458
2.
Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 97(10): 1817-1824, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30054707
3.
Changes in angiogenesis and hypoxia-inducible factor-1α protein expression in relapsed/refractory indolent non-Hodgkin lymphomas.
Br J Haematol
; 163(5): 640-5, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24033233
4.
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions.
Hematol Oncol
; 31(2): 72-8, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23027689
5.
Intraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia.
Mol Med
; 17(7-8): 834-9, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21541442
6.
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.
Leuk Res
; 38(12): 1446-50, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25455656